Table 4.
Summary of Outcomes of CRPC Therapies From Phase III Clinical Trials
| Therapy | Na | PSA Responseb (%) | Radiographic PFS, mos | OS, mos |
|---|---|---|---|---|
| Abiraterone: pre-chemotherapy17 | 546 | 62 | 16.5 | NR |
| Abiraterone: post-chemotherapy18 | 797 | 29 | 5.6 | 14.8 |
| Enzalutamide: pre-chemotherapy19 | 872 | 78 | NR | 32.4 |
| Enzalutamide: post-chemotherapy20 | 800 | 54 | 8.3 | 18.4 |
| Docetaxel (every 3 weeks)21 | 335 | 45 | NR | 18.9 |
| Docetaxel (weekly)21 | 334 | 48 | NR | 17.4 |
| Cabazitaxel22 | 378 | 17.8 | 2.8 | 15.1 |
Abbreviations: CPRC = castration-resistant prostate cancer; NR = not reached; OS = overall survival; PFS = progression-free survival; PSA = prostate specific antigen.
a
Denotes the number of patients in the treatment arm on each respective phase III trial.
b
Defined as a ≥ 50% maximum decline in PSA.